JPH05507504A - 内毒素の毒性処理のための、亜鉛または銅イオンを束縛したアポ・トランスフェリンの利用 - Google Patents
内毒素の毒性処理のための、亜鉛または銅イオンを束縛したアポ・トランスフェリンの利用Info
- Publication number
- JPH05507504A JPH05507504A JP92506475A JP50647592A JPH05507504A JP H05507504 A JPH05507504 A JP H05507504A JP 92506475 A JP92506475 A JP 92506475A JP 50647592 A JP50647592 A JP 50647592A JP H05507504 A JPH05507504 A JP H05507504A
- Authority
- JP
- Japan
- Prior art keywords
- transferrin
- apo
- endotoxin
- zinc
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002158 endotoxin Substances 0.000 title claims description 156
- 239000011701 zinc Substances 0.000 title claims description 144
- 229910052725 zinc Inorganic materials 0.000 title claims description 106
- 108010054176 apotransferrin Proteins 0.000 title claims description 63
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims description 52
- 238000011282 treatment Methods 0.000 title description 11
- 231100000331 toxic Toxicity 0.000 title description 9
- 230000002588 toxic effect Effects 0.000 title description 9
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 title description 7
- 229910001431 copper ion Inorganic materials 0.000 title description 5
- 239000010949 copper Substances 0.000 claims description 37
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 229910052802 copper Inorganic materials 0.000 claims description 25
- 239000012581 transferrin Substances 0.000 claims description 25
- 108060003951 Immunoglobulin Proteins 0.000 claims description 23
- 102000018358 immunoglobulin Human genes 0.000 claims description 23
- 102000004338 Transferrin Human genes 0.000 claims description 22
- 108090000901 Transferrin Proteins 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 231100000419 toxicity Toxicity 0.000 claims description 11
- 230000001988 toxicity Effects 0.000 claims description 11
- 102000004506 Blood Proteins Human genes 0.000 claims description 9
- 108010017384 Blood Proteins Proteins 0.000 claims description 9
- -1 copper cations Chemical class 0.000 claims description 9
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 229940072221 immunoglobulins Drugs 0.000 claims description 4
- 239000012460 protein solution Substances 0.000 claims description 3
- 239000003761 preservation solution Substances 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 229910052723 transition metal Inorganic materials 0.000 claims 1
- 150000003624 transition metals Chemical class 0.000 claims 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 51
- 230000007893 endotoxin activity Effects 0.000 description 34
- 241000894006 Bacteria Species 0.000 description 32
- 241000283073 Equus caballus Species 0.000 description 29
- 241000588724 Escherichia coli Species 0.000 description 29
- 229910052742 iron Inorganic materials 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 27
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 24
- 206010000210 abortion Diseases 0.000 description 24
- 231100000176 abortion Toxicity 0.000 description 24
- 230000000694 effects Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 238000011534 incubation Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 230000007423 decrease Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 230000004071 biological effect Effects 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 9
- 108010088751 Albumins Proteins 0.000 description 8
- 102000009027 Albumins Human genes 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 241000239218 Limulus Species 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 229910000831 Steel Inorganic materials 0.000 description 6
- 238000009739 binding Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 239000010959 steel Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 239000002344 surface layer Substances 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 241000588722 Escherichia Species 0.000 description 4
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000007689 endotoxicity Effects 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 150000002482 oligosaccharides Polymers 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 238000012404 In vitro experiment Methods 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- JMTIXSZQYHAMLY-UHFFFAOYSA-N [P].[Zn] Chemical compound [P].[Zn] JMTIXSZQYHAMLY-UHFFFAOYSA-N 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 231100000284 endotoxic Toxicity 0.000 description 3
- 230000002346 endotoxic effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 229940121657 clinical drug Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 108010072542 endotoxin binding proteins Proteins 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000015994 miscarriage Diseases 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000510930 Brachyspira pilosicoli Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607729 Salmonella enterica subsp. enterica serovar Abortus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- YYJNOYZRYGDPNH-MFKUBSTISA-N fenpyroximate Chemical compound C=1C=C(C(=O)OC(C)(C)C)C=CC=1CO/N=C/C=1C(C)=NN(C)C=1OC1=CC=CC=C1 YYJNOYZRYGDPNH-MFKUBSTISA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 150000002386 heptoses Chemical class 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- MMIPFLVOWGHZQD-UHFFFAOYSA-N manganese(3+) Chemical compound [Mn+3] MMIPFLVOWGHZQD-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000005813 organ abnormality Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4109254A DE4109254A1 (de) | 1991-03-21 | 1991-03-21 | Verwendung von apotransferrin, welches zweiwertige kationen angelagert hat, zur bekaempfung der toxischen wirkung des endotoxins |
| DE4109254,6 | 1991-03-21 | ||
| PCT/DE1992/000230 WO1992016227A1 (de) | 1991-03-21 | 1992-03-17 | Verwendung von apotransferrin, welches zink- oder kupferionen angelagert hat, zur bekämpfung der toxischen wirkung des endotoxins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH05507504A true JPH05507504A (ja) | 1993-10-28 |
Family
ID=6427866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP92506475A Pending JPH05507504A (ja) | 1991-03-21 | 1992-03-17 | 内毒素の毒性処理のための、亜鉛または銅イオンを束縛したアポ・トランスフェリンの利用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5441737A (https=) |
| EP (1) | EP0533872B1 (https=) |
| JP (1) | JPH05507504A (https=) |
| AT (1) | ATE161186T1 (https=) |
| DE (2) | DE4109254A1 (https=) |
| WO (1) | WO1992016227A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6864231B2 (en) * | 2001-01-09 | 2005-03-08 | Pharmachem Laboratories, Inc. | Glycoprotein matrix compositions and methods related thereto |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3844667A1 (de) * | 1988-12-15 | 1990-06-21 | Nitsche Dietrich | Verwendung von transferrin zur bekaempfung der toxischen wirkung des endotoxins bei der endotoxinaemie |
| DE3842143A1 (de) * | 1988-12-15 | 1990-06-21 | Nitsche Dietrich | Verwendung von transferrin zur endotoxinneutralisation |
| US5045466A (en) * | 1989-07-07 | 1991-09-03 | University Of Kansas | Purified mammalian cell binding receptor for bacterial lipopolysaccharide endotoxin and monoclonal antibody |
| DE4008033A1 (de) * | 1990-03-14 | 1991-09-19 | Nitsche Dietrich | Verwendung von lactoferrin zur bekaempfung der toxischen wirkung des endotoxins |
-
1991
- 1991-03-21 DE DE4109254A patent/DE4109254A1/de active Granted
-
1992
- 1992-03-17 DE DE59209069T patent/DE59209069D1/de not_active Expired - Fee Related
- 1992-03-17 US US07/952,861 patent/US5441737A/en not_active Expired - Fee Related
- 1992-03-17 EP EP92906947A patent/EP0533872B1/de not_active Expired - Lifetime
- 1992-03-17 AT AT92906947T patent/ATE161186T1/de not_active IP Right Cessation
- 1992-03-17 WO PCT/DE1992/000230 patent/WO1992016227A1/de not_active Ceased
- 1992-03-17 JP JP92506475A patent/JPH05507504A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0533872B1 (de) | 1997-12-17 |
| ATE161186T1 (de) | 1998-01-15 |
| DE59209069D1 (de) | 1998-01-29 |
| EP0533872A1 (de) | 1993-03-31 |
| WO1992016227A1 (de) | 1992-10-01 |
| US5441737A (en) | 1995-08-15 |
| DE4109254A1 (de) | 1992-09-24 |
| DE4109254C2 (https=) | 1993-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vadalasetty et al. | Influence of silver nanoparticles on growth and health of broiler chickens after infection with Campylobacter jejuni | |
| Bullen et al. | Sepsis: the critical role of iron | |
| Bullen et al. | Bacterial iron metabolism in infection and immunity | |
| Nussler et al. | Leukocytes, the Janus cells in inflammatory disease | |
| JPH09502987A (ja) | 殺菌性／浸透性が向上した（ｂｐｉ）タンパク質生成物および抗生物質の投与によるグラム陰性細菌感染の治療方法 | |
| JPH07504918A (ja) | 細菌感染の予防及び処理のための二酸化塩素含有組成物 | |
| JPS5920229A (ja) | 強化されたオプソニン活性を有する組成物 | |
| Yousefi et al. | Hydroxy decenoic acid down regulates gtfB and gtfC expression and prevents Streptococcus mutans adherence to the cell surfaces | |
| BRONER et al. | Effect of scavengers of oxygen-derived free radicals on mortality in endotoxin-challenged mice | |
| US5240909A (en) | Use of lactoferrin for treatment of toxic effects of endotoxins | |
| Kobayashi | Airway biofilm disease | |
| US8859626B2 (en) | Anti-virulence compositions and methods | |
| Brock | Lactoferrin structure-function relationships: an overview | |
| JPH05501416A (ja) | エンドトキシンの毒性作用の治療のためのラクトフェリンの使用 | |
| JPH05507504A (ja) | 内毒素の毒性処理のための、亜鉛または銅イオンを束縛したアポ・トランスフェリンの利用 | |
| EP0374311B1 (en) | Urease antigen product | |
| Bastos et al. | Campylobacter fetus cellulitis | |
| Juttukonda et al. | Manganese and nutritional immunity | |
| Chandrasekhar et al. | Comparative evaluation of antibacterial activity of probiotics SK12 and SM18: An in vitro study | |
| Lauterbach et al. | Pentoxifylline treatment of sepsis of premature infants: preliminary clinical observations | |
| Chan et al. | A case of bordetella bronchiseptica Bacteremia in a patient with decompensated liver cirrhosis | |
| DE3842143C2 (https=) | ||
| Bayed et al. | Susceptibility pattern in pathogenic bacteria isolated from clinical specimens of wounds antimicrobial effects of camel’surfline compared with antibiotic | |
| JPH04187640A (ja) | 経口・経皮免疫機能促進剤、動物用経口・経皮免疫機能促進剤 | |
| Neanover | Effects of Oxygen Levels and Short Chain Fatty Acid Exposure on Antibiotic Susceptibility in Listeria monocytogenes |